Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 9/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19698928 | 0.81 | HCAR2 (0.43) | HCAR3HCAR2GCKVNN1MAPK1 | |
| SCHEMBL24445684 | 0.78 | HCAR2 (0.41) | HCAR3HCAR2GCKVNN1MAPK1 | |
| SCHEMBL19705749 | 0.77 | GPBAR1 (0.38) | — | |
| SCHEMBL22639598 | 0.75 | — | — | |
| SCHEMBL22363321 | 0.74 | TAAR1 (0.35) | MAPTMAPK1CYP2C9CYP2C19 | |
| SCHEMBL28531102 | 0.72 | HCAR3 (0.41) | HCAR3HCAR2MAPTVNN1MAPK1 | |
| SCHEMBL21783356 | 0.71 | ATM (0.40) | MAPT | |
| SCHEMBL3374192 | 0.71 | RAB9A (0.44) | HCAR3HCAR2MAPTVNN1MAPK1 | |
| SCHEMBL19374835 | 0.70 | LMNA (0.41) | MAPTMAPK1 | |
| SCHEMBL14928310 | 0.70 | KMT2A (0.45) | HCAR3HCAR2MAPTVNN1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190308962-A1 | FXR (NR1H4) Modulating Compounds | GILEAD SCIENCES, INC. (US) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308962-A1 | FXR (NR1H4) Modulating Compounds | NR1H4, NR1H2, NR1H3 | HCAR3 205/4885HCAR2 152/4885MAPT 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.